Compare Cytokinetics Inc (CYTK) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs SMX Security Matters plc — how do they compare? Cytokinetics Inc trades at $62.74 (market cap $8.62B), while SMX Security Matters plc trades at $3.74 (market cap $4.13M). The key difference: Cytokinetics Inc is far larger — about 2087.2× SMX Security Matters plc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| CYTK | SMX | |
|---|---|---|
Market Cap | $8.62B | $4.13M |
Volume | 2,594,626 | 124,362 |
Sector | Health | Industrials |
52-Week High | $87.26 | $74.08K |
52-Week Low | $54.76 | $3.79 |
Typical Hold Time | 19 Days | — |
Enterprise Value | $8.72B | -$27.20M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
SMX trades at $4.21, up 7.95% today, but exhibits severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22% for 2025. The technical outlook is bearish based on moving averages, though oscillators like the RSI signal oversold conditions. Recent news highlights the company's focus on its Digital Material Passport platform for recycled plastics and material traceability, aiming to capitalize on circular economy trends.
The investment outlook is highly speculative. While the stock appears cheap on P/B (0.09) and EV/EBITDA (0.02) multiples, this reflects extreme financial losses and operational cash burn. Positive media coverage contrasts with the fundamental reality, creating significant risk. Upside depends entirely on the successful commercialization of its technology, which remains unproven given the current lack of revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
